Valeo Financial Advisors LLC acquired a new position in shares of C.R. Bard, Inc. (NYSE:BCR) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 529 shares of the medical instruments supplier’s stock, valued at approximately $170,000.

A number of other institutional investors also recently bought and sold shares of the business. Alps Advisors Inc. increased its stake in C.R. Bard by 0.3% during the 2nd quarter. Alps Advisors Inc. now owns 1,921 shares of the medical instruments supplier’s stock worth $607,000 after acquiring an additional 5 shares during the period. KCM Investment Advisors LLC increased its stake in shares of C.R. Bard by 0.5% in the 2nd quarter. KCM Investment Advisors LLC now owns 2,187 shares of the medical instruments supplier’s stock valued at $691,000 after purchasing an additional 10 shares during the last quarter. Parallel Advisors LLC increased its stake in shares of C.R. Bard by 2.8% in the 2nd quarter. Parallel Advisors LLC now owns 513 shares of the medical instruments supplier’s stock valued at $164,000 after purchasing an additional 14 shares during the last quarter. Montag A & Associates Inc. increased its stake in shares of C.R. Bard by 3.9% in the 2nd quarter. Montag A & Associates Inc. now owns 2,125 shares of the medical instruments supplier’s stock valued at $672,000 after purchasing an additional 80 shares during the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA increased its stake in shares of C.R. Bard by 7.8% in the 2nd quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 1,375 shares of the medical instruments supplier’s stock valued at $441,000 after purchasing an additional 100 shares during the last quarter. Hedge funds and other institutional investors own 79.35% of the company’s stock.

Several equities analysts have recently issued reports on the company. ValuEngine lowered C.R. Bard from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Barclays lifted their price target on C.R. Bard from $245.00 to $337.00 and gave the company an “equal weight” rating in a research note on Monday, November 6th. Cowen reiterated a “hold” rating and issued a $317.00 price target on shares of C.R. Bard in a research note on Friday, November 3rd. Needham & Company LLC reiterated a “hold” rating on shares of C.R. Bard in a research note on Thursday, October 26th. Finally, Jefferies Group reiterated a “hold” rating and issued a $317.00 price target on shares of C.R. Bard in a research note on Thursday, September 14th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and one has given a strong buy rating to the company. C.R. Bard has an average rating of “Hold” and a consensus price target of $303.50.

In related news, VP Frank Lupisella, Jr. sold 9,173 shares of the business’s stock in a transaction on Wednesday, October 18th. The stock was sold at an average price of $325.00, for a total transaction of $2,981,225.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director David M. Barrett sold 3,344 shares of the business’s stock in a transaction on Monday, October 30th. The stock was sold at an average price of $327.31, for a total value of $1,094,524.64. The disclosure for this sale can be found here. Insiders have sold a total of 191,593 shares of company stock worth $62,655,513 in the last 90 days. 0.80% of the stock is currently owned by corporate insiders.

Shares of C.R. Bard, Inc. (NYSE:BCR) traded up $0.03 during mid-day trading on Wednesday, reaching $332.09. The company had a trading volume of 500,500 shares, compared to its average volume of 660,314. The company has a market cap of $24,204.64, a price-to-earnings ratio of 28.67, a P/E/G ratio of 2.54 and a beta of 0.52. C.R. Bard, Inc. has a twelve month low of $216.55 and a twelve month high of $337.73. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.72 and a quick ratio of 1.37.

C.R. Bard (NYSE:BCR) last issued its quarterly earnings data on Wednesday, October 25th. The medical instruments supplier reported $3.02 earnings per share for the quarter, topping analysts’ consensus estimates of $2.96 by $0.06. The business had revenue of $989.80 million for the quarter, compared to analyst estimates of $990.64 million. C.R. Bard had a return on equity of 48.28% and a net margin of 14.75%. C.R. Bard’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.64 EPS. sell-side analysts anticipate that C.R. Bard, Inc. will post 11.89 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 29th. Investors of record on Friday, December 8th will be given a dividend of $0.26 per share. The ex-dividend date of this dividend is Thursday, December 7th. This represents a $1.04 dividend on an annualized basis and a yield of 0.31%. C.R. Bard’s dividend payout ratio is currently 13.70%.

TRADEMARK VIOLATION WARNING: “Valeo Financial Advisors LLC Invests $170,000 in C.R. Bard, Inc. (BCR) Stock” was first posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece can be read at https://www.watchlistnews.com/valeo-financial-advisors-llc-invests-170000-in-c-r-bard-inc-bcr-stock/1761521.html.

About C.R. Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard and related companies with MarketBeat.com's FREE daily email newsletter.